Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
Rhea-AI Summary
Altimmune (Nasdaq: ALT) will report fourth quarter and full year 2025 financial results on March 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a business update.
According to Altimmune, the live webcast will be available on the company's Investor Relations website, dial-in registration is required for participants, and a replay will be accessible for up to three months.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
ALT was down 0.22% with below-average volume, while only one tracked peer in momentum (LRMR) showed a move, heading down by about 5.88% without news. Broader biotech peers in the affinity list mostly showed positive price changes, suggesting ALT’s action around the earnings-date news was stock-specific rather than part of a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 29 | Offering closing | Neutral | +9.8% | Closed $75M registered direct offering to fund Phase 3 pemvidutide trial. |
| Jan 27 | Offering pricing | Negative | -17.1% | Priced $75M registered direct offering of common stock and pre-funded warrants. |
| Jan 05 | Regulatory designation | Positive | +16.5% | Received FDA Breakthrough Therapy Designation for pemvidutide in MASH. |
| Dec 19 | Clinical data update | Positive | -22.8% | Reported positive 48-week IMPACT Phase 2b pemvidutide MASH trial results. |
| Dec 01 | Leadership change | Neutral | -6.3% | Announced CEO transition and succession plan effective January 1, 2026. |
Recent history shows mixed reactions: positive clinical and regulatory milestones sometimes saw sharp selloffs, while a financing closing produced a notable gain, indicating inconsistent trading behavior around fundamentally positive events.
Over the past few months, Altimmune has reported several major developments. Positive IMPACT Phase 2b data and FDA Breakthrough Therapy Designation for pemvidutide in MASH around Dec 19, 2025 and Jan 5, 2026 led to large but opposite price moves. A CEO succession announced on Dec 1, 2025 drew a moderate decline. More recently, a $75 million registered direct offering priced on Jan 27, 2026 and closed on Jan 29, 2026 produced a sharp drop followed by a rebound. Today’s earnings-date notice fits into this cadence of frequent catalysts.
Regulatory & Risk Context
The company has an amended Form S-3 shelf filed on Nov 13, 2025 to register up to $400,000,000 of various securities, with usage evidenced by at least one 424B5 offering on Jan 28, 2026. The shelf was not yet effective at the time of the amendment, and any future sales would be for general corporate and development purposes.
Market Pulse Summary
This announcement sets March 5, 2026 as the next checkpoint, when Altimmune will report Q4 and full-year 2025 results and host a business update call at 8:30 a.m. ET. In light of recent financings, clinical milestones in MASH, and leadership changes, that event may provide added clarity on pemvidutide’s development plans, capital deployment, and strategic priorities. Investors may watch for updates that contextualize prior offerings and regulatory progress.
AI-generated analysis. Not financial advice.
GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026.
Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Investor Contact:
Lee Roth
Burns McClellan
lroth@burnsmc.com
Media Contact:
Real Chemistry
altimmune@realchemistry.com
This press release was published by a CLEAR® Verified individual.
FAQ
When will Altimmune (ALT) report Q4 and full year 2025 results and when is the conference call?
How can investors access the Altimmune (ALT) March 5, 2026 webcast and register for the conference call?
Will Altimmune (ALT) provide a replay of the March 5, 2026 earnings call and for how long?
What topics will Altimmune (ALT) management cover during the March 5, 2026 business update?
What time and where should shareholders go to listen to Altimmune (ALT)’s March 5, 2026 investor call?
